All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
XS-0622-ZP3310 | Anti-αVβ3 h(VHH1-VHH2-CD28-CD3ζ) Biepitopic CAR, pCDCAR1 | Human | VHH1-VHH2-CD28-CD3ζ | Lentiviral vector | T Cell | ||||
XS-0622-ZP3482 | Anti-αVβ3 h(VHH1-VHH2-4-1BB-CD3ζ) Biepitopic CAR, pCDCAR1 | VHH1-VHH2-4-1BB-CD3ζ | Lentiviral vector | T Cell | |||||
XS-0822-YF917 | Anti-Human αvβ3 (XW-917) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-917 | Humanized | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF918 | Anti-Human αvβ3 (XW-918) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-918 | Humanized | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF1837 | Anti-Human αvβ3 (XW-917) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-917 | Humanized | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF1838 | Anti-Human αvβ3 (XW-918) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-918 | Humanized | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF2757 | Anti-Human αvβ3 (XW-917) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-917 | Humanized | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF2758 | Anti-Human αvβ3 (XW-918) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-918 | Humanized | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF8642 | TS-Fluc Anti-Human αvβ3 scFv (XW-917) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-917 | Humanized | 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
XS-0822-YF8643 | TS-Fluc Anti-Human αvβ3 scFv (XW-918) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-918 | Humanized | 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
XS-0822-YF9051 | TS-Fluc Anti-Human αvβ3 scFv (XW-917) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-917 | Humanized | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF9052 | TS-Fluc Anti-Human αvβ3 scFv (XW-918) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-918 | Humanized | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF9460 | TS-Fluc Anti-Human αvβ3 scFv (XW-917) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-917 | Humanized | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF9461 | TS-Fluc Anti-Human αvβ3 scFv (XW-918) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-918 | Humanized | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF9869 | TS-IL15 SA Anti-Human αvβ3 scFv (XW-917) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-917 | Humanized | 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
XS-0822-YF9870 | TS-IL15 SA Anti-Human αvβ3 scFv (XW-918) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-918 | Humanized | 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
XS-0822-YF10278 | TS-IL15 SA Anti-Human αvβ3 scFv (XW-917) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-917 | Humanized | 7H-YB-IL15 SA-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF10279 | TS-IL15 SA Anti-Human αvβ3 scFv (XW-918) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-918 | Humanized | 7H-YB-IL15 SA-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF10687 | TS-IL15 SA Anti-Human αvβ3 scFv (XW-917) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-917 | Humanized | 7H-YB-IL15 SA-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF10688 | TS-IL15 SA Anti-Human αvβ3 scFv (XW-918) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-918 | Humanized | 7H-YB-IL15 SA-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION